What it is
This stack combines CJC-1295 without DAC with ipamorelin. The two compounds act on different GH-axis pathways, but the combo itself does not have a clean human evidence base as a combined product.
Evidence boundary
Investigational. Evidence for the individual ingredients does not establish a validated stack protocol.
Trial evidence
- PMID 42578445 — Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
- PMID 42160466 — Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
- PMID 42123471 — Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
Preparation and measurement
Reconstitution: 10 mg vial + 2 mL BAC = 5 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–2 (titration) | 200 mcg | 4 U (0.04 mL) | 1–3× daily | 1.4 mg/week |
| Weeks 3–4 | 300 mcg | 6 U (0.06 mL) | 1–3× daily | 2.1 mg/week |
| Weeks 5–6 | 400 mcg | 8 U (0.08 mL) | 1–3× daily | 2.8 mg/week |
| Weeks 7–12 (target) | 550 mcg | 11 U (0.11 mL) | 1–3× daily | 3.85 mg/week |
Weeks 1–2 (titration)
- Dose
- 200 mcg
- Draw / measure
- 4 U (0.04 mL)
- Frequency
- 1–3× daily
- Weekly total
- 1.4 mg/week
Weeks 3–4
- Dose
- 300 mcg
- Draw / measure
- 6 U (0.06 mL)
- Frequency
- 1–3× daily
- Weekly total
- 2.1 mg/week
Weeks 5–6
- Dose
- 400 mcg
- Draw / measure
- 8 U (0.08 mL)
- Frequency
- 1–3× daily
- Weekly total
- 2.8 mg/week
Weeks 7–12 (target)
- Dose
- 550 mcg
- Draw / measure
- 11 U (0.11 mL)
- Frequency
- 1–3× daily
- Weekly total
- 3.85 mg/week
Weekly totals apply only during the active phase.
Titration rules
- Titration schedule (per peptide; doses are combined CJC-1295 + Ipamorelin in equal parts):
- Weeks 1–2 (titration): 200 mcg per dose, 1–3× daily.
- Weeks 3–4: 300 mcg per dose, 1–3× daily.
- Weeks 5–6: 400 mcg per dose, 1–3× daily.
- Weeks 7–12 (target): 550 mcg per dose, 1–3× daily (pre-bed mandatory; AM/pre-workout optional).
- Cycle structure: 12–16 weeks continuous, then 4-week break. An alternative schedule runs 12 weeks on, 4 weeks off, repeat.
- Timing: Pre-bed dose 30–60 min before sleep, fasted (no food/protein in last 2h). Pre-workout dose ~30 min before training, fasted.
- Bloodwork cadence: IGF-1 every 8–12 weeks. An alternative schedule includes cortisol monitoring given ipamorelin’s near-zero (but non-zero) cortisol effect.
Cycle length and breaks
An alternative schedule runs 12 weeks on, 4 weeks off, repeat. Effects on body composition, sleep quality, and recovery accumulate gradually over 8–12 weeks.
What to monitor
- Sleep and recovery
- Hunger changes
- Water retention
- Injection-site reactions
Practical rules
- If notes are being compared, keep the timing consistent.
- Avoid eating right after dosing if that is part of the note set.
- Keep sleep and training steady.
- Rotate sites.
Related protocols
CJC-1295 (DAC) Peptide Protocol & DosingSermorelin Peptide Protocol & DosingTesamorelin Peptide Protocol & DosingCJC-1295 (No DAC) + Ipamorelin Blend Protocol Supply & lot verification
Availability and batch-linked COA records for CJC-1295 (No DAC) + Ipamorelin Stack & Dosing are kept with the current product listing.
View availability & COA → Verification notes